Dr Michael Keating- MD Anderson Cancer Center, Texas, USA
Dr Michael Keating discusses his pick of the research presented at ASH 2010. This includes trials looking at new tyrosine kinase inhibitors that target LIM-kinase, Syk, PI 3-kinase delta or BTK. Due to the low levels of toxicity, these TKIs are potentially ideal front line therapies for older cancer patients. Dr Keating talks about what we can expect from the upcoming International Workshop on CLL (IWCLL) which will be held in Texas on 28-30 October 2011.